Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
SAN DIEGO, May 31, 2017 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the Jefferies 2017 Global Healthcare Conference to be held in New York City from June 6 - 9, 2017.
The aTyr management team will present an overview of the Company during a presentation at 2:00 p.m. ET on Friday, June 9, 2017. The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com. An audio replay will be available for at least 30 days following the initial presentation webcast.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological pathways. To date, the Company has generated three innovative therapeutic candidate programs based on its knowledge of Physiocrine biology in three different therapeutic areas. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 190 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune imbalance for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
Contact: Mark Johnson Sr. Director, Investor Relations [email protected] 858-223-1163
